Angle PLC - Issue of LTIP Options and Share Options
|
For immediate release |
|
ANGLE plc ("the Company")
Issue of LTIP Options and Share Options
ANGLE plc (AIM: AGL; OTCQX: ANPCY), a world-leading liquid biopsy company, announces that, under the Remuneration Policy approved by the shareholders at the Annual General Meeting on
Share options are issued to align the interest of employees with shareholders and help motivate, reward and retain staff. The allocation of LTIP Options and Staff Share Options approved by the Remuneration Committee also takes into account that, for the third consecutive year, no bonuses for executives and staff were awarded in order to help conserve cash and extend the Company's cash runway. While a staff share option award was made in 2024, the allocation for executive directors reflects a catch-up award for 2024 as well as a 2025 award following the agreement to waive cash bonus entitlements for both 2023 and 2024 operating years.
Following the issue of these options, the Company will have outstanding options over a total of up to 51,369,480 Ordinary Shares, representing approximately 13.7% of its issued and to be issued share capital, which is within the Remuneration Policy approved limit of up to 16%.
The exercise price for the Staff Share Options is
The LTIP Options have performance conditions as set out below, a performance period of three years and an additional holding period of two years. Subject to the rules of the LTIP, awards will vest only to the extent that the performance conditions have been met during the performance period and the underlying shares may only be traded once the holding period is completed. The LTIP Options contain normal "good leaver", "bad leaver" and change of control provisions, and malus and clawback provisions will apply under certain circumstances.
The intention of the LTIP is to reward tangible increases in shareholder value, in this case above the share price of the last funding round (
|
|
|
|
Allocation of LTIP options |
|||||
|
Share price CAGR on funding round |
Multiple of funding round share price |
Multiple of current share price |
Proportion vesting |
Andrew Newland |
Ian Griffiths |
Total |
||
|
< 20% |
< 1.73 |
<2.66 |
0% |
0 |
0 |
0 |
||
|
> 20% |
> 1.73 |
>2.66 |
20% |
1,440,000 |
960,000 |
2,400,000 |
||
|
> 25% |
> 1.95 |
>3.00 |
50% |
3,600,000 |
2,400,000 |
6,000,000 |
||
|
> 30% |
> 2.20 |
>3.38 |
100% |
7,200,000 |
4,800,000 |
12,000,000 |
||
The non-executive directors of the Company do not hold share options.
As at
The below notification made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
|||||
|
a)
|
Name
|
Andrew Newland
|
||||
|
2
|
Reason for the notification
|
|||||
|
a)
|
Position/status
|
Chief Executive Officer |
||||
|
b)
|
Initial notification /Amendment
|
Initial notification |
||||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|||||
|
a)
|
Name
|
ANGLE plc |
||||
|
b)
|
LEI
|
213800BY11K6W3NMS374 |
||||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
|||||
|
a)
|
Description of the financial instrument, type of instrument
Identification code
|
Options over Ordinary shares of
ISIN: GB0034330679
|
||||
|
b)
|
Nature of the transaction
|
Grant of nil-cost LTIP options over ordinary shares under the ANGLE plc LTIP Scheme |
||||
|
c)
|
Price(s) and volume(s)
|
|
||||
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
N/A
|
||||
|
e)
|
Date of the transaction
|
|
||||
|
f)
|
Place of the transaction
|
Outside a trading venue |
||||
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
|||||
|
a)
|
Name
|
Ian Griffiths |
||||
|
2
|
Reason for the notification
|
|||||
|
a)
|
Position/status
|
Finance Director |
||||
|
b)
|
Initial notification /Amendment
|
Initial notification |
||||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|||||
|
a)
|
Name
|
ANGLE plc |
||||
|
b)
|
LEI
|
213800BY11K6W3NMS374 |
||||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
|||||
|
a)
|
Description of the financial instrument, type of instrument
Identification code
|
Options over Ordinary shares of
ISIN: GB0034330679
|
||||
|
b)
|
Nature of the transaction
|
Grant of nil-cost LTIP options over ordinary shares under the ANGLE plc LTIP Scheme |
||||
|
c)
|
Price(s) and volume(s)
|
|
||||
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
N/A
|
||||
|
e)
|
Date of the transaction
|
|
||||
|
f)
|
Place of the transaction
|
Outside a trading venue |
||||
For further information:
|
ANGLE plc |
+44 (0) 1483 343434 |
|
Andrew Newland, Chief Executive Ian Griffiths, Finance Director |
|
|
Berenberg (NOMAD and Broker) Toby Flaux, Ciaran Walsh, Milo Bonser |
+44 (0) 20 3207 7800 |
|
FTI Consulting Simon Conway, Ciara Martin Matthew Ventimiglia (US) |
+44 (0) 203 727 1000 +1 (212) 850 5624 |
For Frequently Used Terms, please see the Company's website on https://angleplc.com/investor-relations/glossary/
Notes for editors
About ANGLE plc
ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected CTC harvesting technology known as the Parsortix® PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis.
ANGLE's commercial businesses are focusing on clinical services and diagnostic products. The clinical services business is offered through ANGLE's GCLP-compliant laboratories. Services include custom made assay development and clinical trial testing for pharma. Products include the Parsortix system, associated consumables and assays.
Over 100 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit www.angleplc.com
Any reference to regulatory authorisations such as FDA clearance, CE marking or UK MHRA registration shall be read in conjunction with the full intended use of the product:
The Parsortix® PC1 system is an in vitro diagnostic device intended to enrich circulating tumor cells (CTCs) from peripheral blood collected in K2EDTA tubes from patients diagnosed with metastatic breast cancer. The system employs a microfluidic chamber (a Parsortix cell separation cassette) to capture cells of a certain size and deformability from the population of cells present in blood. The cells retained in the cassette are harvested by the Parsortix PC1 system for use in subsequent downstream assays. The end user is responsible for the validation of any downstream assay. The standalone device, as indicated, does not identify, enumerate or characterize CTCs and cannot be used to make any diagnostic/prognostic claims for CTCs, including monitoring indications or as an aid in any disease management and/or treatment decisions.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE